Filtered By:
Procedure: Liver Transplant

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 13440 results found since Jan 2013.

In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts.
We report that LNA and UNA modified siRNA and sisiRNA improve the efficacy in target knockdown as compared with unmodified siRNA in the tumor xenografts without formulation. However, the level of off-target gene regulation in both the tumor and the liver correlated with the increase in efficacy in target knockdown, unless the seed region of the siRNA was modified. PMID: 21687525 [PubMed - as supplied by publisher]
Source: Artificial DNA: PNA and XNA - November 19, 2015 Category: Genetics & Stem Cells Tags: Artif DNA PNA XNA Source Type: research

Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies. PMID: 30084326 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Marinho HS, Marcelino P, Soares H, Corvo ML Tags: Curr Pharm Des Source Type: research

 IL-1β siRNA adenovirus benefits liver regeneration by improving mesenchymal stem cells survival after acute liver failure.
CONCLUSION: IL-1? siRNA adenovirus could enhance MSC ability of tissue regeneration through increasing its survival rate. Accordingly, combination of IL-1? siRNA adenovirus and MSC had a synergistic effect on acute liver failure. PMID: 26845604 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - February 5, 2016 Category: Gastroenterology Tags: Ann Hepatol Source Type: research

Delivering siRNA Compounds During HOPE to Modulate Organ Function: A Proof-of-concept Study in a Rat Liver Transplant Model
Conclusions. FAS inhibition through siRNA therapy decreases the severity of IRI after LT in a SCS protocol; however the association of siRNA therapy with a HOPE perfusion model is very challenging. Future studies using better designed siRNA compounds and appropriate doses are required to prove the siRNA therapy effectiveness during liver HOPE liver perfusion.
Source: Transplantation - August 1, 2022 Category: Transplant Surgery Tags: Original Basic Science Source Type: research

Preparation and evaluation of a non-viral gene vector for SiRNA: Multifunctional envelope-type nano device.
Authors: Zhang Y, Wei H, Xu L, Yan G, Ma C, Yu M, Wei C, Sun Y Abstract We prepared and evaluated a multifunctional envelope-type nano device (MEND) as a liver-targeting and long-circulation carrier for SiRNA. The polymer GA-PEG-Pp-DOPE was synthesized by modifying polyethylene glycol (PEG) with glycyrrhetinic acid (GA), peptide (Pp), and dioleoyl phosphoethanolamine (DOPE). The Pp is a substrate of matrix metalloproteinase 2. MEND was prepared with GA-PEG-Pp-DOPE and cationic phospholipids by the filming-rehydration method, and the orthogonal test was applied to optimize the prescription. The results of the biolog...
Source: Artificial Cells, Nanomedicine and Biotechnology - December 12, 2015 Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research

Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
CONCLUSIONS: Our data demonstrated that VEGF silencing could suppress cells proliferation, promote cells apoptosis and reduce HCC angiogenesis through inactivation of VEGF/PI3K/AKT signaling pathway. PMID: 26744866 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 15, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Fight Aging! Newsletter, January 9th 2023
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 8, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Exercise interventions for adults after liver transplantation
CONCLUSIONS: Based on very low-certainty evidence in our systematic review, we are very uncertain of the role of exercise training (aerobic, resistance-based exercises, or both) in affecting mortality, health-related quality of life, and physical function (i.e. aerobic capacity and muscle strength) in liver transplant recipients. There were few data on the composite of cardiovascular mortality and cardiovascular disease, cardiovascular disease post-transplantation, and adverse event outcomes. We lack larger trials with blinded outcome assessment, designed according to the SPIRIT statement and reported according to the CONS...
Source: Cochrane Database of Systematic Reviews - May 19, 2023 Category: General Medicine Authors: Èlia Pérez-Amate Marta Roqu é-Figuls Miguel Fern ández-González Maria Gin é-Garriga Source Type: research

Prostaglandins for adult liver transplanted recipients
CONCLUSIONS: Eleven trials evaluated prostaglandins in adult liver transplanted recipients. Based on low-certainty evidence, prostaglandins may reduce all-cause mortality up to one month; may cause little to no difference in serious adverse events, liver retransplantation, early allograft dysfunction, primary non-function of the allograft, and length of hospital stay; and may have a large reduction in the development of acute kidney injury requiring dialysis. We do not know the effect of prostaglandins on adverse events considered non-serious. We lack adequately powered, high-quality trials evaluating the effects of prosta...
Source: Cochrane Database of Systematic Reviews - August 4, 2023 Category: General Medicine Authors: Zubair Umer Mohamed Christi Titus Varghese Abish Sudhakar Lakshmi Kumar Unnikrishnan Gopalakrishnan Dinesh Balakrishnan Ramachandran Narayanamenon Surendran Sudhindran Source Type: research

Machine perfusion in liver transplantation
CONCLUSIONS: In situations where the decision has been made to transplant a liver donated after circulatory death or donated following brain death, end-ischaemic HOPE will provide superior clinically relevant outcomes compared with SCS alone. Specifically, graft survival is improved (high-certainty evidence), serious adverse events are reduced (moderate-certainty evidence), and in donors after circulatory death, clinically relevant ischaemic biliary complications are reduced (high-certainty evidence). There is no good evidence that NMP has the same benefits over SCS in terms of these clinically relevant outcomes. NMP does ...
Source: Cochrane Database of Systematic Reviews - September 12, 2023 Category: General Medicine Authors: Samuel J Tingle Joseph J Dobbins Emily R Thompson Rodrigo S Figueiredo Balaji Mahendran Sanjay Pandanaboyana Colin Wilson Source Type: research

Exercise interventions for adults after liver transplantation
CONCLUSIONS: Based on very low-certainty evidence in our systematic review, we are very uncertain of the role of exercise training (aerobic, resistance-based exercises, or both) in affecting mortality, health-related quality of life, and physical function (i.e. aerobic capacity and muscle strength) in liver transplant recipients. There were few data on the composite of cardiovascular mortality and cardiovascular disease, cardiovascular disease post-transplantation, and adverse event outcomes. We lack larger trials with blinded outcome assessment, designed according to the SPIRIT statement and reported according to the CONS...
Source: Cochrane Database of Systematic Reviews - May 19, 2023 Category: General Medicine Authors: Èlia Pérez-Amate Marta Roqu é-Figuls Miguel Fern ández-González Maria Gin é-Garriga Source Type: research

Prostaglandins for adult liver transplanted recipients
CONCLUSIONS: Eleven trials evaluated prostaglandins in adult liver transplanted recipients. Based on low-certainty evidence, prostaglandins may reduce all-cause mortality up to one month; may cause little to no difference in serious adverse events, liver retransplantation, early allograft dysfunction, primary non-function of the allograft, and length of hospital stay; and may have a large reduction in the development of acute kidney injury requiring dialysis. We do not know the effect of prostaglandins on adverse events considered non-serious. We lack adequately powered, high-quality trials evaluating the effects of prosta...
Source: Cochrane Database of Systematic Reviews - August 4, 2023 Category: General Medicine Authors: Zubair Umer Mohamed Christi Titus Varghese Abish Sudhakar Lakshmi Kumar Unnikrishnan Gopalakrishnan Dinesh Balakrishnan Ramachandran Narayanamenon Surendran Sudhindran Source Type: research

HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
CONCLUSIONS: Statins may reduce cardiovascular events in kidney transplant recipients, although treatment effects are imprecise. Statin treatment has uncertain effects on overall mortality, stroke, kidney function, and toxicity outcomes in kidney transplant recipients. Additional studies would improve our confidence in the treatment benefits and harms of statins on cardiovascular events in this clinical setting. PMID: 24470059 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 3, 2014 Category: Journals (General) Authors: Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
CONCLUSIONS: MMF was superior to AZA for improvement of graft survival and prevention of acute rejection after kidney transplantation. These benefits must be weighed against potential harms such as tissue-invasive CMV disease. However, assessment of the evidence on safety outcomes was limited due to rare events in the observation periods of the studies (e.g. malignancies) and inconsistent reporting and definitions (e.g. infections, adverse events). Thus, balancing benefits and harms of the two drugs remains a major task of the transplant physician to decide which agent the individual patient should be started on. PMID...
Source: Cochrane Database of Systematic Reviews - December 3, 2015 Category: Journals (General) Authors: Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K Tags: Cochrane Database Syst Rev Source Type: research